title: Limited effect of rituximab on thrombocytopaenia and anticardiolipin antibodies in a patient with primary antiphospholipid syndrome.
authors.forename: P R J
authors.initials: PR
authors.lastname: Ames
authors.forename: C
authors.initials: C
authors.lastname: Tommasino
authors.forename: G
authors.initials: G
authors.lastname: Fossati
authors.forename: G
authors.initials: G
authors.lastname: Scenna
authors.forename: V
authors.initials: V
authors.lastname: Brancaccio
authors.forename: F
authors.initials: F
authors.lastname: Ferrara
mesh_terms: D000328:Adult; D017153:Antibodies, Anticardiolipin / Q000097:blood*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D016736:Antiphospholipid Syndrome / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007075:Immunoglobulin M / Q000097:blood; D007155:Immunologic Factors / Q000627:therapeutic use; D008297:Male; D000069283:Rituximab; D013921:Thrombocytopenia / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D017153:Antibodies, Anticardiolipin; D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D007075:Immunoglobulin M; D007155:Immunologic Factors; D000069283:Rituximab